Oral low‐dose chemotherapy: Successful treatment of an alveolar rhabdomyosarcoma during pregnancy
Pediatric Blood & Cancer2011Vol. 58(1), pp. 104–106
Citations Over TimeTop 14% of 2011 papers
Meinolf Siepermann, Ewa Kościelniak, Tobias M. Dantonello, Dirk Klee, Joachim Boos, Barbara Krefeld, Arndt Borkhardt, Thomas Hoehn, Alexzander Asea, Rüdiger Wessalowski
Abstract
We report for the first time the impact of neoadjuvant oral low-dose chemotherapy consisting of oral trofosfamide, idarubicin, and etoposide (O-TIE) in the case of alveolar rhabdomyosarcoma (RMS) in the lower jaw of an 18-year-old woman at 27 weeks of gestation, without fetal complications and a highly efficient anti-tumor response. Our study suggests the possible application of O-TIE treatment in a neoadjuvant setting during pregnancy and recommends a schedule that can be considered for the treatment of patients with high-risk sarcomas who cannot be treated with intensive chemotherapy for various reasons.
Related Papers
- → Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells(1999)11 cited
- → Refractory alveolar rhabdomyosarcoma in an 11-year-old male(2021)3 cited
- Intensive chemotherapy in induction and consolidation for De Novo adult acute myeloid leukemia using sequential courses of high dose cytarabine, idarubicin, and etoposide: a randomized trial of the Australian leukaemia and lymphoma group (ALLG).(2001)
- → Pharmacokinetic Basis for an Oral Chemotherapy with Idarubicin and Etoposide: Dose-Dependent Biological Effects of Topoisomerase-II-Inhibitors(1998)1 cited
- → Alveolar Sinonasal Rhabdomyosarcoma in Adults: A Case Report(2013)